Kornimate/medical-research-clean huggingface dataset:
vienna versus sars-cov-2 virus study

Conditions: SARS-CoV-2; COVID-19

Summary: this study examines the seroprevalence against sars-cov-2 in health care workers and patients at the vienna general hospital.

this study consists of 2 parts: a longitudinal study enrolling 3,000 health care professionals at the vienna general hospital testing their antibody status 6 times over a period of 12 months (cohort a), and a serial cross-sectional study of 3,000 patients (i.e., a total of 9,000 patients) admitted to the vienna general hospital for non-covid-19-related symptoms at 3 different time points during this pandemic (cohort b).

Eligibility criteria:
cohort a: inclusion criteria: * physicians * nursing staff * midwives * medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants) * administrative personnel with patient contact exclusion criteria: * not employed at the medical university of vienna or the vienna general hospital * no signed informed consent cohort b: inclusion criteria: ● patients with available residual serum samples exclusion criteria: ● serum samples from covid-19 triage units at the vienna general hospital

Keywords: covid-19 sars-cov-2 immunity antibodies virus respiratory virus immunoglobulins
a double-masked comparison of fid 123320 ophthalmic solution to vehicle for the reduction of ocular redness

Conditions: Ocular Redness

Summary: the purpose of this study is to assess the safety and efficacy of apraclonidine hydrochloride ophthalmic solution 0.125% when compared to vehicle, in relieving redness of the eye due to minor eye irritations. this study will be conducted in the united states.

the study will consist of six (6) scheduled visits: screening and/or baseline visit (day -7 to -1), eligibility confirmation/randomization/1st treatment visit (day 1), week 2 follow-up visit (day 14), week 4 follow-up visit (day 28), week 8 follow-up/treatment discontinuation visit (day 56) and exit visit (day 63). the expected individual duration of participation in the study is approximately 10 weeks with approximately 56 days of exposure to the investigational product.

Eligibility criteria:
key inclusion criteria: * capable of giving signed informed consent; * willing and able to follow all instructions and attend all study visits; * able to self-administer eye drops- in the opinion of the investigator; * history of redness relief drop use within the last 6 months, or a desire to use over-the-counter (otc) eye drops for redness relief; * females capable of becoming pregnant: agree to urine pregnancy tests and the use of medically acceptable forms of birth control throughout the study; * ocular health within normal limits, including best-corrected visual acuity (bcva) of 20/40 or better in each eye as measured using a snellen chart; * ocular redness at baseline as specified in the protocol; * other protocol-specified inclusion criteria may apply. key exclusion criteria: * known contraindications or sensitivities to the use of any of the investigational drug(s) or their components, or any other medication required by the protocol; * ocular surgical interventions within 6 months prior to visit 1 or during the study; * ocular conditions that, in the opinion of the investigator, could affect the subject's safety or study parameters (i.e., could affect ocular redness, intraocular pressure, or eyelid position); * disallowed medications or devices as specified in the protocol; * planned surgery (ocular or systemic) during the study period or within 30 days after the study period; * other protocol-defined exclusion criteria may apply.

Keywords: eye redness irritated eyes
the effects of methylphenidate on the cognitive function of older people with mild cognitive impairment

Conditions: Mild Cognitive Impairment (MCI)

Summary: background: the increase in life expectancy and the rise in the ratio of older to younger people in the population has resulted in an increase in the number of those suffering from a decrease in cognitive ability, such as mild cognitive impairment (mci). methylphenidate can improve cognitive ability, mainly in memory and executive function. working hypothesis and aims: this study examines the effect of ritalin treatment in older people suffering from mci. our hypothesis is that treatment with ritalin will improve cognitive function in those suffering from mci, especially in the domains of attention and executive function. methods a randomized, double-blind, case-control study. 120 patients older than 65 years of age diagnosed as suffering from mci in the past year in geriatric assessment facilities in beersheva. patients will be randomized in equal groups to either the study group (ritalin treatment) and control group (placebo). each participant will attend the geriatric unit for four consecutive days: on the day prior to beginning the intervention participants will undergo cognitive assessment at 9:00 am. on the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of ritalin (10, 20 and 30mg) every day of intervention. participants in the control group will receive placebo. two hours after taking the drug or placebo participants in both groups will be assessed cognitively by means of mindstreams and moca (montreal cognitive assessment). expected results: ritalin treatment will improve the cognitive function of the subjects, mainly in the domains of concentration and executive function


Eligibility criteria:
inclusion criteria: * \>65 years old * male and female * living in the community exclusion criteria: * suffer from unstable conditions, for example, unstable heart disease, severe heart failure, severe renal failure, cirrhosis, blood pressure above 160/100; * patient who suffer from glaucoma, hyperthyroididsm, epilepsy, patients after stroke, patient with parkinson's disease, major depression, schizophrenia or receiving neuroleptic drugs; * patient who suffer from dementia * patients that recieve treatment in acetylcholinesterase inhibitors or memantine. * known sensitivity to methylphenidate.

Keywords: methylphenidate, elderly, mild cognitive impairment
vulvar mucosal specialty clinic chart review

Conditions: Vulvar Disease; Lichen Sclerosus; Lichen Planus; Vulvodynia

Summary: this study aims to develop a clinical database of patients presenting with vulvar complaints in order to comprehensively assess the presentation and current trends in management of vulvar disease.

vulvar disorders are common, but their frequency and importance are often under-recognized. the spectrum of vulvar disease is vast and includes congenital malformations, inflammatory mucocutaneous diseases, blistering and erosive diseases, benign and malignant tumors, autoimmune disorders, infectious diseases, and various idiopathic conditions. evaluation and management of genital complaints and dermatoses are complicated by the frequent multifactorial nature of vulvar symptoms and variable clinical expressions of disease on the vulva. in many cases, empiric treatment is instituted in the absence of a definitive diagnosis. of note, expertise in the diagnosis and management of vulvar disorders is often lacking on the parts of gynecology, dermatology and primary care physicians. the investigators seek to analyze the data on this patient population at northwestern memorial hospital (nmh) and the outpatient clinics of the northwestern memorial faculty foundation (nmff) to better define the clinical spectrum of vulvar disease. the investigators will also assess approaches to the diagnosis and management of patients with vulvar disease with attention given to clinical outcome and the impact on quality of life. this information with help the investigators to better understand the scope of care these patients currently receive, to identify deficits in current practice, and to advance potential new standards of care.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * patients seen at northwestern medical group department of dermatology who were seen by dr. bethanee schlosser and/or other members of the vulvar mucosal specialty clinic team in any of their respective clinic settings. exclusion criteria: * patients who refuse complete mucocutaneous examination. * patients who refuse recommended diagnostic procedures. * pregnant women or prisoners.
elastic stable intramedullary nailing of dislocated clavicle fractures in children

Conditions: Dislocated Clavicular Fracture Treated With Elastic Stable Intramedullary Nailing

Summary: most clavicular fractures in children can be treated conservatively. our own study showed a benefit towards much lower pain and better cosmesis in adolescents when treated with elastic stable intramedullary nailing. the first 20 patients treated with this method will be examined for functional (constant and murley-score) and cosmetic results as well as ultrasound-morphology of both clavicles and patients'satisfaction (css-8). further on, all complications and problems will be documented.


Eligibility criteria:
inclusion criteria: * only dislocated shaft fractures or pseudarthrosis after conservative treatment of dislocated csf in children and adolescents treated with elastic stable intramedullary nailing exclusion criteria: * age \> 17 years * pathologic fractures * lateral or medial fractures of the clavicle

Keywords: esin clavicular fracture dislocation children adolescents
comparison of surecall® labor monitor® and tocodynamometer measurement in preterm and term pregnant women

Conditions: Pregnancy

Summary: this measurement study was designed to evaluate the performance of surecall® labor monitor® (surecall®) compared to the predicate tocodynamometer device (toco) in preterm and term pregnant patients.

the surecall® labor monitor® (surecall®) is a transabdominal electromyography monitor intended to measure uterine activity. it is intended for use on pregnant women, with singleton pregnancies, using surface electrodes on the maternal abdomen. the device is intended for use by healthcare professionals in a clinical setting. this measurement study was designed to evaluate the performance of surecall® labor monitor® (surecall®) compared to the predicate tocodynamometer device (toco) in pregnant laboring preterm patients, nonlaboring preterm patients, and nonlaboring term patients. this study involved 25 women at a gestational age of 36 weeks or less and 5 women at a gestation age of greater than 36 at five clinical sites. each study subject was instrumented with two technologies for measuring uterine activity: 1. standard tocodynamometer attached to the maternal abdomen, 2. surecall® with a set of abdominal surface electrodes for uterine electromyography attached to the maternal abdomen subjects did not recieve any interventions as a part of this study.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * informed consent required exclusion criteria: * multifetal pregnancy * informed consent not given
macular hole surgery with and without internal limiting membrane peeling：a systematic review and meta-analysis

Conditions: Macular Holes

Summary: since kelly and wendel first reported successful closure of idiopathic macular holes (mh) by vitrectomy in 1991, many surgical modifications have been made to improve the anatomical and visual outcomes of this surgery. recently, internal limiting membrane (ilm) peeling has become used widely as an adjunctive procedure during mh surgery because the removal of ilm is thought to reduce the tangential traction on the macula, a major factor in the pathogenesis of idiopathic macular holes. however, the role of ilm peeling in macular hole surgery is not yet well defined. to the best of our knowledge, there is no meta-analysis on comparison of the efficacy of ilm peeling and suture for mh surgery. this study reviewed the published literature comparing surgical results with and without ilm peeling and and performed a meta-analysis to determine whether there is any benefit or detriment anatomically and/or visually.


Eligibility criteria:
inclusion criteria: * eligible participants are those with idiopathic ftmh in stages 2-3, of less or equal than 18 months duration (based on symptoms reported by the patient) and with a visual acuity equal to or worse than 20/40 in the study eye. exclusion criteria: * patients with idiopathic ftmh stages 2-3 but longer than 18 months duration or with other causes of decreased vision (e.g. corneal scarring, age-related macular degeneration, diabetic retinopathy, glaucoma if central and/or paracentral absolute visual field defects are present) and * those with ftmh related to high myopia (\> 6 dioptres) or trauma will be excluded from the study.

Keywords: macular holes internal limiting membrane peeling surgery
long-term follow-up study of bhc001 for tdt

Conditions: Thalassemia, Beta

Summary: observe long-term safety risk and long-term efficacy after intravenous infusion of bhc001 in tdt subjects.

observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of bhc001 in tdt subjects.

Eligibility criteria:
inclusion criteria: 1. provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) 2. treated with brl-101 for therapy of transfusion-dependent β-thalassemia. exclusion criteria: - there are no exclusion criteria for this study
observational study of subcutaneous immunoglobulin (cutaquig) in patients with primary and secondary immunodeficiency.

Conditions: Primary Immune Deficiency Disorder; Secondary Immune Deficiency

Summary: this study will assess the relative safety, tolerability, and participant satisfaction in participants using the rapid manual push method with cutaquig®. the hypothesis being that treatment with cutaquig® by rapid manual push method will improve the safety, tolerability and patient satisfaction of participants with pid or sid. cutaquig® by rapid push is already approved in canada and has proven to be efficacious in preventing significant infection. however, relative safety, tolerability, and patient satisfaction have not been studied in these patients. the information gained from this study will improve the safety and tolerability knowledge database and will support the optimal use of cutaquig® - thus benefitting both physicians and patients.

primary and secondary immunodeficiency diseases (pid and sid, respectively) affect the development and/or function of the immune system, resulting in increased frequency of infection. treatment of these disorders using cutaquig® (a subcutaneous immunoglobulin infusion (scig)) was licensed in canada in 2018 and has proven to be effective in preventing significant infection. other brands of scig can be given by the participant using a syringe (called rapid manual push method), which shows the same efficacy as administration by a programmable pump. the rapid manual push method has the potential to improve quality of life, reduce infusion time, and reduce the cost of administration. this study will evaluate the safety, tolerability, and patient satisfaction of cutaquig® by the rapid manual push method in participants with pid or sid. it will also compare the efficacy of cutaquig with prior scig treatment, if applicable, in participants with pid or sid.

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years) * who have pid or sid requiring igg replacement therapy * for whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of cutaquig® 165 mg/ml at home * having signed an informed consent form exclusion criteria: -patients currently participating in another interventional study at the time of inclusion
study evaluating the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis

Conditions: Arthritis, Psoriatic; Psoriasis

Summary: this study aims to collect australian data on the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis. in addition the study will assess disease severity and quality of life in australian patients with psoriasis attending specialist dermatology clinics.

consecutive psoriasis patients seen at each site will be invited to participate in the study

Eligibility criteria:
inclusion criteria: * diagnosis of plaque psoriasis * \>= 18 years of age * able to complete english-language questionnaires exclusion criteria: * participation in an interventional clinical trial in previous 3 months * known rheumatologist-confirmed psoriatic arthritis

Keywords: psoriasis psoriatic arthritis epidemiology prevalence
effects of hiit on metabolic syndrome

Conditions: Dyslipidemias; Metabolic Syndrome; Sedentary Behavior; Obesity; Blood Pressure

Summary: the project aims to find out the differences between two different types of structured training interventions have on the lipid profile of persons with diagnosed dyslipidemia. each training intervention will last for 12 weeks. subjects participating in the project will undergo a series of tests before and after the training intervention which will allow us to make conclusions.

the purpose of this project is to compare the effect that two different types of aerobic training modes have on the lipid profile of subjects with pre-symptoms of metabolic syndrome. one training mode will involve high-intensity interval training and the other will involve medium intensity continuous training. the desired outcomes of this project are to know the effects of both modes of training have on the long-term on the lipid profile in order to help develop a nonpharmacologic alternative to prevent or treat metabolic syndrome and to know how affective and enjoyment responses are affected by the different modes of training. the project lasts for 16 weeks. training will take place during weeks 3 and 14 of the project. the project will be described fully to the participants during the 1st week. in addition to this, their rights as participants will be explained in addition to any possible ethical issues that might require clarifying. once the subjects have agreed to take part in the research they will undergo a series of tests in order to asses their cardiorespiratory fitness and their lipids profile. before starting the training intervention participants will be randomly assigned to one of the 3 different groups; control, medium intensity continuous training and low volume high-intensity interval training. between weeks 3 and 14 subjects will take part in 3 training sessions per week. at week 15 and 16 subjects will undergo the same tests as during week 1 and 2.

Eligibility criteria:
inclusion criteria: * fasted blood glucose \>100 mg/dl * total cholesterol \>200 mg/dl * blood pressure \>130/90 mmhg * do not partake in more than 150 min/week of moderate to vigorous exercise exclusion criteria: * existing or past medical history of vascular disease, cancer, diabetes, osteoporosis, neurological, kidney, pulmonary, digestive (coeliac disease), thyroidal disease. * musculoskeletal injuries * neuromuscular disorders or injuries * individuals with a pacemaker

Keywords: hiit high intensity interval training medium intensity continuous training interval training exercise physical activity exercise training
pathophysiological study of allergic contact dermatitis to para-phenylenediamine (ppd). analysis of cellular and molecular targets in skin inflammation

Conditions: Allergic Contact Dermatitis

Summary: the current knowledge of the pathophysiology of allergic contact dermatitis is based on the murine model. in this model, cd8+ t cells are effector cells, and cd4+ t cells regulate the response by limiting the expansion of cd8+ t cells. the goal of this study is to characterize the pathophysiology of contact dermatitis, with patients allergic to para-phenylenediamine (ppd). we suppose that the cd8+ t cells are the effectors of the allergic contact dermatitis, although the regulator cells belong to the lt cd4+ population. we will test our hypothesis on blood samples, and cutaneous biopsies of patients allergic to ppd.


Eligibility criteria:
inclusion criteria: for both groups: * patients aged from 18 to 65 years old. * both genders eligible for study. * female participants must use a contraceptive method. * feasibility of patch testing. * participants must be able to understand and sign the informed consent, and comply with all aspects of the protocol. * patients must be registered in a social security system or with a health insurance coverage  first group: allergic patients * patients with allergic contact dermatitis to para-phenylenediamine (ppd) based on a history of ppd contact dermatitis and positive ppd patch tests.  second group : healthy volunteers * no history of ppd allergic contact dermatitis, with a negative ppd patch test. exclusion criteria: * pregnant or lactating women. * evolutive skin disease on the testing zone (lower back). * patients with a clinically significant disease (chronic, recurrent or active). * systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid treatment the week before the patch testing. * local or systemic drug use which interacts with the outcome measures. * exposure to sun or uv radiations, 15 days before the patch testing. * patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision. * patients subject to a protection measure. * patients in a critical medical situation. * patients with a personal situation judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient. * linguistic barrier or psychological profile preventing the patient from signing the consent form. * patient still in an exclusion period following the participation in another clinical trial. * patients having earned more than 4500€ in indemnities for participation in clinical trials during the previous 12 months, including this study.

Keywords: allergic contact dermatitis para-phenylenediamine effector cells regulatory cells pathophysiology
a study of eltrekibart (ly3041658) in adult participants with moderate to severe hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (hs) for further clinical development. the study will last approximately 62 weeks and may include up to 31 visits.


Eligibility criteria:
inclusion criteria: * have a diagnosis of hs for at least 12 months. * have hs lesions in at least 2 distinct anatomical regions. at least 1 of the lesions must be at least hurley stage ii or iii. * have an (abscess plus inflammatory nodule) count of at least 5. * agree to use topical antiseptics daily. * had an inadequate response or intolerance to a 28-day course of oral antibiotics. exclusion criteria: * have more than 20 draining fistulae. * have had surgical treatment for hs in the last 4 weeks before randomization. * have an active skin disease or condition, that could interfere with the assessment of hs. * have a current or recent acute, active infection. * are immunocompromised. * have a history of chronic alcohol abuse, iv drug abuse, or other illicit drug abuse within 1 year before screening.